We are live on ! Find out more
TXG icon

10x Genomics

326 hedge funds and large institutions have $2.01B invested in 10x Genomics in 2025 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 108 increasing their positions, 99 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $5.72M | Put options by funds: $2.61M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

14% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 57

2% more funds holding

Funds holding: 320 → 326 (+6)

9% more repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 99

6% more capital inflows, than outflows

Capital inflows: $265M | Capital outflows: $251M

1.56% less ownership

Funds ownership: 107.49% → 105.93% (-1.6%)

Holders
326
Holders Change
+6
Holders Change %
+1.88%
% of All Funds
3.92%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
65
Increased
108
Reduced
99
Closed
57
Calls
$5.72​M
Puts
$2.61​M
Net Calls
+$3.11​M
Net Calls Change
-⁠$50​K

TXG Hedge Fund Activity: Q4 2025 in Review

326 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2025, worth a combined $2.01B — up 40% from $1.44B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new TXG positions and 57 closed out — a net gain of 8 holders — while 108 added to existing stakes and 99 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $52.3M. The largest seller was Millennium Management, cutting an estimated $63.4M.

  • 326 institutional investors held 10x Genomics (TXG) as of Q4 2025, up from 320 in Q3 2025.
  • Funds reported $2.01B of 10x Genomics stock for Q4 2025, up 40% quarter-over-quarter.
  • 65 funds opened new 10x Genomics positions in Q4 2025 and 57 closed out, a net change of +8 holders.
  • The largest 10x Genomics buyer in Q4 2025 was Fidelity Investments, an estimated $52.3M added.
  • The largest 10x Genomics seller in Q4 2025 was Millennium Management, an estimated $63.4M sold.

Based on aggregated 13F filings for Q4 2025.